Gentian Diagnostics ASA has entered into a distribution agreement for the Gentian Cystatin C Immunoassay with a global diagnostics company. The cooperation is positioned towards the diagnosis and treatment of renal disease, with launch scheduled for the second half of 2022, initially in the USA and Canada. Gentian's new distributor develops and distributes in vitro diagnostic systems mainly destined for biological analysis in medical laboratories on a worldwide basis.

These automated analysers meet the needs of various users including private laboratories, clinics and university hospitals. While the clinical use of Cystatin C can have far-reaching benefits across all patient groups, certain vulnerable patient populations may experience a greater benefit. Some specific patient groups would receive more accurate results with Cystatin C because its concentrations are independent of muscle mass and show less age and gender-related variation relative to creatinine.